Idorsia Heralds Second Positive Study of Sleep Drug Daridorexant

FDA Filing At End Of 2020

 
• By Kevin Grogan

The Swiss biotech will be hoping that the improved daytime functioning seen with daridorexant in trials will allow the drug to complete in the DORA class led by Merck & Co's Belsomra and Eisai's Dayvigo.

Yawning
Insomniacs want to sleep at night and not suffer during the day • Source: Shutterstock

More from Clinical Trials

More from R&D